We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

KMK Kromek Group Plc

0.05 (1.05%)
01 Dec 2023 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Kromek Group Plc LSE:KMK London Ordinary Share GB00BD7V5D43 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  0.05 1.05% 4.80 1,082,791 14:41:03
Bid Price Offer Price High Price Low Price Open Price
4.60 5.00 4.80 4.75 4.75
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Miscellaneous Metal Ores,nec 17.31M -6.1M -0.0141 -3.40 20.73M
Last Trade Time Trade Type Trade Size Trade Price Currency
17:07:10 O 355,846 4.80 GBX

Kromek (KMK) Latest News

Kromek (KMK) Discussions and Chat

Kromek Forums and Chat

Date Time Title Posts
28/11/202316:20Kromek Group PLC7,020
05/1/202209:19Kromek Group (KMK) - Overvalued AIM mugging182

Add a New Thread

Kromek (KMK) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type

Kromek (KMK) Top Chat Posts

Top Posts
Posted at 02/12/2023 08:20 by Kromek Daily Update
Kromek Group Plc is listed in the Miscellaneous Metal Ores,nec sector of the London Stock Exchange with ticker KMK. The last closing price for Kromek was 4.75p.
Kromek currently has 431,852,000 shares in issue. The market capitalisation of Kromek is £20,728,896.
Kromek has a price to earnings ratio (PE ratio) of -3.40.
This morning KMK shares opened at 4.75p
Posted at 25/10/2023 23:10 by ark87
Do we think Simon thompson actually owns any shares? He has been tipping it all the way down from 20p. If he's legit and and buying his own tips, he should be down huge on his intial purchase and given his confidence he should have been topping up the whole way down.Yet, he shows no signs of the annoyance a legit holder would be be feeling. I'm going to guess he is in some way being paid for the incredible promotion job he giving KMK and does'nt own any KMK shares or maybe a small token holding. Not to be trusted and should be investigated... Just my opinion.
Posted at 23/10/2023 21:54 by aqc888
Unbelievable, tipped again by Simon Thompson.

The article reads exactly the same as his many many previous articles when the share price was 20p, 16p, 12p etc etc.
Posted at 19/10/2023 07:12 by quepassa
Anyone who subscribed to the mid-year Placing & capital raising exercise at 5p, has already lost c. 33% of their capital in less than six months.

In my view, the resolutely downwards share price graph is pointing to sub 3p.

Posted at 09/9/2023 21:26 by 33mick
To put things in context and the short term (which it is )financing arrangements being hopefully sorted soon.
Philips is a £4+ billion company that has been designing state of the art hi tech medical equipment and systems for longer than anyone's been alive reading this, if you look you will see Philips name has cropped up numerous times in Kmk past news releases and broker reports, they were working with kmk's US subsidiary EV Products who they took over 10 years ago.
Analogic Corp a US privately owned company was sold 6 years ago for 1.1 bill dollars with est 500+ mil dollar annual revenues.
Spectrum Dynamics the the first OEM to fully adopt Kmk's CZT into thier premier CT product are est to be valued at 50-100 mil dol.
Plus the un-named new Asian 1.4 mil CZT SPECT imaging customer announced in May this year...

these companies owners, CEO's, management ,design and development teams have thier money, reputations and future growth & profitability all firmly aligned and committed to using kmk's CZT gamma modules after years of collaboration in most cases.
and I have no reason to doubt kmk's confident statements predicting the likes of Fuji medical, United Imaging and the others they are working with will not follow suit.
But obviously AQC knows better!
and presumably thinks all these bods have made a disastrous error of judgement.
Posted at 09/6/2023 14:35 by aqc888
Doug, I got it wrong. Happy to admit it and have a healthy bank balance. Had some fierce debates with Quepassa, who himself used to be invested here. I feel I got to the bottom of the situation, through debate and facts, and saw the share price plunge by 70% since I sold.

I noted some claims by Kromek weren’t working out, I noted the ceo wasn’t taking his own medicine, I noted deadlines and targets were being forgotten about.

When the facts changed I changed my mind. Mick33 and others here seem desperate to dig their heads deeper in the sand every time they hear of failure. With the share price at 5p (from 25p when first invested) I suppose that’s the only hope they have. Some kind of Stockholm syndrome I guess
Posted at 25/5/2023 12:19 by ark87
I posted this on 11th May. This share is dodgy... very very dodgy... and honestly needs investigating...

"It’s so obvious what’s going on here it’s laughable. They have engineered a rise in the share price to sucker people into the placing and the rampers (strategic investor and his merry men) are out in full force. Once they get the placing through , the share price will collapse below 5p. EXACT same thing happened with covid detector placing."
Posted at 09/5/2023 19:21 by aqc888
For some context;

Pivotal year unfolding for Kromek - 18/1/22
Share price 14.5p

Winners in an uncertain world - 16/5/22
Share price 9.7p

Kromek’s record sales visibility is materially undervalued - 2/8/22
Share price 9.5p

A biological detection winner - 11/22
Share price 8.75p

This stock is about to turn world-leading technology into profit - 2/23

Analysts think this stock's share price will quadruple - 4/23
Share price 6.85p

Buy into Kromek's £7.5mn open offer of new shares - today
Share price 5p

…. It goes back way further when share price was way way higher…

“Don't worry about Kromek's revenue fall“ - 1/2019
Share price 26p
Posted at 27/4/2023 14:17 by skyship
Analysts think this stock's share price will quadruple

It has announced a company-transforming seven-year agreement highlighting its bargain share price

April 19, 2023.....By Simon Thompson

Ground-breaking seven-year agreement with a Tier One OEM
Agreement to develop next-generation CT detector technology
Positive trading update
Sedgefield-based Kromek (KMK:6.85p), a radiation detection technology company focused on the medical imaging and nuclear markets, has announced a company-transforming seven-year agreement with a top-tier original equipment manufacturer (OEM) to develop cadmium zinc telluride (CZT)-based detectors for the client’s advanced medical imaging scanners.

Following a short development period, the agreement will transition into a longer commercial supply phase. The enhanced image quality associated with the technology could enable the earlier detection of diseases, such as heart disease and cancer, thereby improving patient outcomes and increasing efficiencies within healthcare settings.

Analysts at Equity Development note that the medical imaging market is divided between computed tomography (CT) and single-photon emission CT (SPECT)-based products and is dominated by four tier-one suppliers: Phillips Medical Systems, Siemens Healthineers GmbH, Canon Medical Systems and GE Healthcare.

House broker FinnCap estimates that the CT medical imaging scanner market was worth $6.7bn in 2022, with the tier-one suppliers controlling 85 to 90 per cent of the market. Market research company Market Data Forecast estimates that the CT scanner market could be worth $7.2bn in 2023, growing to $9bn by 2028, the implication being that this could be a $10bn market by 2030.

Value of agreement to Kromek
On this basis, FinnCap calculates that the CZT-based share of the CT scanner market could be worth $2bn in 2030, assuming the new technology scanners take a 20 per cent share of the total market, suggesting an addressable market opportunity of $300mn-$400mn for a tier-one supplier. This would imply revenue to Kromek of $64mn (£51mn) in 2030, generating $26mn (£20mn) of gross profit on a margin of 40 per cent and annual cash profit of £10mn-£15mn.

Moreover, assuming the tier-one OEM converts 50 per cent of its scanners to CZT over a 10-year period, it implies that the agreement has a net present value (NPV) of £39mn-£59mn (9p to 14p a share) using discount rates of 10 to 15 per cent, respectively. In a more optimistic scenario in which the conversion rate rises to 75 per cent, the NPV of the agreement rises to £58mn-£87mn (13p to 20p a share), a hefty sum in relation to Kromek’s current market capitalisation of £28.8mn (6.85p).

The strategic value of CZT to tier-one OEMs in their next-generation diagnostic imaging development was brought into sharp focus in September 2021 when Canon acquired Kromek’s rival Redlen Technologies for a valuation of $290mn, or a multiple of 20 to 33 times its annual revenue (£ to £8.4mn) at the time. Kromek is now the only independent developer and producer of CZT-based detection systems. Equity Development has a read-across implied valuation for Kromek’s medical imaging division of £247mn (57p), or 8.5 times its current market capitalisation, based on a multiple of 25 times 2023-24 revenue estimates of £9.9mn for the unit.
Posted at 08/3/2023 17:01 by mrwarrenb
I had a virtual meeting this morning with both Arnab Basu (CEO) and Paul Farquhar (CFO). Also present was Harry Chathli from Gracechurch PR.

Rather than colour this post with my own personal opinions, I’ve tried to provide an objective summary below of what we discussed. The call lasted only 30 minutes and we were only allowed to talk about publicly-available information, so apologies if your question wasn’t covered.

Share price: the company doesn't control the markets, so this is largely beyond their control. The company is back on a growth path with a strong trajectory and the drivers of its two main businesses, medical imaging and CBRN detection, are fundamentally strong.

Executive purchases of shares: “Senior management and the Board of Directors don’t have many opportunities to buy shares outside of capital raises, but whenever they can, they do.” CFO Paul Farquhar owns £5,000 worth of shares, in his wife’s name, which were worth £10,000 at the time they were purchased. Understand that shareholders are keen to see them have “skin in the game”.

Cash position: this is closely managed at all times. No cash was consumed during the H1 23 reporting period – the first time this has happened. Unable to comment about future requirements or capital raises. The company considers both debt and equity for the its financing requirements.

DARPA contract: this is coming to an end and there don’t appear to be any immediate follow-ons, but on a related note, Kromek was awarded a £5m biological threat-detection contract by the UK Government in November 2022, which will be delivered over a three-year period, and this does include an option for extended maintenance services after the initial term.

Sales: Strong revenue growth in both medical imaging and CBRN detection. The fundamentals of both sectors are strong (ageing population -> better and more cost-effective diagnostics required; governments reviewing their biosecurity strategies in the light of the Ukraine situation -> improved detection needs, especially in cities) and Kromek is now well-positioned to benefit. Unable (for confidentiality reasons) to provide any updates on the timing of any new contract wins/announcements.

Costs: the fundamental building blocks of the business are now in place and the cost base won’t continue to scale up as revenues scale up. Costs are constantly under review and the organisation is already lean. There is no wholesale cost-reduction programme planned.

China contract inventory: the inventory from the China contract, which was due to be delivered in 2020 does not have a shelf-life and will not “go bad”. It can be sold to other customers over the coming years, which would bring cash into the business and free up cash that is currently tied up in the balance sheet. China is starting to open up again now and a recovery in business there is expected. Previously, it wasn’t practical to travel there, because of the lengthy isolation periods required as a result of covid restrictions. Any future sales in the region might be direct or via a distributor.

Potential takeover target?: unable to comment on this. Could only say that, as a listed company, they are committed to remaining independent.

Engagement with shareholders: acknowledgement this could have been better and committed to holding an investor webinar/Q&A session, chaired by Harry Chathli of Gracechurch PR. No concrete timing for this, but likely to be scheduled around the results. The company welcomes visitors to its County Durham global HQ.

Overall: Dr Basu reiterated the strong, positive growth story in revenues, with 40+% gross margins. The Spectrum Dynamics deal from October 2022 continues to ramp up each quarter. Acknowledge shareholders’ frustration with the share price performance but feel this is largely outside their control. No forecasts or updates about when the business might become profitable.

Thanks again to everyone on the board who submitted questions in advance. The more searching ones were batted away or couldn't be answered, because of confidentiality reasons, but senior management is most definitely aware now (if it wasn't before) of shareholders' concerns and expectations.
Posted at 10/8/2022 02:36 by ark87
The shareprice was down until IC tipped it (again). Unfortunately as you can see from KMK share price performance since inception (51p to to 14p over 9 years) will be short lived unless some game changing news is on horizon which at this point seems doubtful.
Kromek share price data is direct from the London Stock Exchange

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: +44 (0) 203 8794 460 |